An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00552396
• Other study ID #: IPH2101-103
• Status: Completed
• Phase: Phase 1
• First received: May 21, 2007
• Last updated: May 24, 2012
• Start date: May 2007
• Est. completion date: January 2011

Study information

• Verified date: May 2012
• Source: Innate Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Development of new treatments for diseases such as multiple myeloma is a focus for research. The research being conducted is on treatment called Anti-KIR (1-7F9), which activates the body's own cells to kill tumor cells. This is different from many other treatments where chemicals are given to kill tumor cells. The purpose of the study is to determine a safe dose of Anti-KIR (1-7F9) to administer in humans and to gain information about its effectiveness in the treatment of multiple myeloma.

Description:

Trial Design:

The trial is an open-label, dose-escalation trial to determine the safety and tolerability of Anti-KIR (1-7F9) in subjects with relapsed or refractory multiple myeloma (RRMM). A 3+3 design will be employed for the first dosing cycle at each dose level. The 7 planned dose levels are 0.0003 mg/kg, 0.003 mg/kg, 0.015 mg/kg, 0.075 mg/kg, 0.3 mg/kg, 1.0 mg/kg and 3.0 mg/kg. The subjects will receive up to a total of 4 administrations of Anti-KIR (1-7F9) with a dosing interval between each administration of 4 weeks. Safety, toxicity, PK (pharmacokinetic) and PD (pharmacodynamic) obtained in the first 4 weeks after dosing per group will be the basis for dose-escalation decisions. There will be follow-up visits every week the one month after the first administration and every two weeks following the second, third and fourth administrations. After the last administration there will be follow-up visits every month until KIR occupancy is no longer detected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)

2. Bone marrow plasmacytosis > 10% (as determined by bone marrow aspirate) or plasmacytoma

3. Relapse or progression after at least one prior systemic treatment regimen for Multiple Myeloma (MM) as evidenced by = 25% increase in the M-protein as compared to the best response from the previous treatment regimen.

3a. One prior therapy for multiple myeloma, Measurable disease, as defined by persistent presence of serum and/or urine monoclonal protein or abnormal serum free light chain ratio following the prior treatment.

a. Only for the last seven patients enrolled into the cohort 7 or Maximal Tolerated Dose (MTD).

4. Full recovery from acute toxicities of prior anti-MM therapies. 5. Peripheral blood (Natural Killer) NK cells (Absolute CD16, 56)= 0.05 x 109/L (50/mm3) 6. Detectable binding of Anti-KIR (1-7F9) to subject NK cells 7. Age = 18 years 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2 9. Clinical laboratory values at screening:

• serum creatinine < grade 2 toxicity i.e. 1.5x upper limit of institutional normal value

• total bilirubin < 1.5x upper limit of institutional normal value

• Aspartate aminotransferase (AST) < or = 3x upper limit of institutional normal value

• Absolute Neutrophil Count (ANC) >1.2 x109/L

• Platelets >70x109/L

Exclusion Criteria:

1. Known or suspected allergy to trial product or related products

2. Previous participation in this trial (dosed)

3. Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (appropriate methods include abstinence and the following methods: diaphragm, condom (by the partner), intrauterine device, sponge, spermicide or oral contraceptives)

4. Male subjects who are sexually active and have not been surgically sterilized must be informed that they must either use a condom during intercourse, ensure that their partners practices contraception, or they must refrain from sexual intercourse during the study and until 1 month after completion of the trial.

5. Use of an investigational agent within 30 days of the first dose of study drug (or five half-lives of any antibody).

6. Current treatment with any other anti-MM therapy excluding prophylactic bisphosphonates.

7. Radiotherapy against bone lesions within 4 weeks or visceral lesions within 8 weeks of Screening.

8. Thalidomide or bortezomib treatment within 14 days of Screening.

9. Cytotoxic chemotherapy (excluding thalidomide or bortezomib) or corticosteroid treatment within 28 days of Screening.

10. Subjects with non-secretory multiple myeloma

11. Subjects on dialysis

12. Use of myeloid growth factor within 28 days of screening

13. G-CSF treatment within 28 days of screening

14. Active autoimmune disease

15. Active infectious disease (e.g. HIV, chronic hepatitis, etc.) as judged by the investigator.

16. New York Heart Association (NYHA) class III-IV heart failure

17. Severe neurological / psychiatric disorder as judged by the investigator

18. Clinical evidence of an active second malignancy, with the exception of basal cell carcinoma or in situ carcinoma of cervix.

19. Subjects with a history of allogenic transplantation.

20. Subject who have undergone autologous transplantation within the last 3 months.

21. Mental incapacity or inadequate understanding of English.

22. Any serious medical condition that in the opinion of the investigator, disqualifies the subject for inclusion in the trial.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Anti-KIR (1-7F9)
human monoclonal antibody

Locations

Country	Name	City	State
United States	Ohio State University Medical Center	Columbus	Ohio
United States	Indiana University Cancer Center	Indianapolis	Indiana
United States	Mont Sinai Medical Center	New York City	New York
United States	Cancer Therapy Research Center at UTHSCSA	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Innate Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment	The maximum tolerated dose (MTD) is the highest dose level below the maximum administered dose (MAD) where none or 1 out of 6 subjects have a DLT.	From start of the treatment to end of study	Yes
Secondary	Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration	Cmax was obtained from the plasma concentration versus time data after IV administration of IPH2101.	Anti-KIR (1-7F9) concentrations were measured prior to infusion at 0.167, 1, 3, 6, 12 and 24 hours and then on Days 7, 14 and 21 after the start of the first dose administration	No
Secondary	Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration	AUC(INF), area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration within the dosing interval was calculated for Cycle 1.	Anti-KIR (1-7F9) concentrations were measured prior to infusion at 0.167, 1, 3, 6, 12 and 24 hours and then on Days 7, 14 and 21 after the start of the first dose administration	No
Secondary	Number of Evaluable Patients With Stable Disease. "Evaluable" is Defined as 2 Consecutive M Protein Assessments	Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease	From start of the treatment to end of study or disease progression	No

External Links

•   Indiana University Cancer Center 'Find a Clinical Trial'